Author

V. L. Dao Thi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:cell type annotation· 3 Research Focus:host-pathogen & immune response· 3 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A.-K. Mehnert· 2 shared D. Todt· 2 shared E. Steinmann· 2 shared J. Hu· 2 shared L. Maurer· 2 shared M. Kloehn· 2 shared R. M. Fu· 2 shared S. Urban· 2 shared

Activity by Year

2023-2024 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A.-K. Mehnert

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Hepatitis E Virus-induced antiviral response by plasmacytoid dendritic cells is modulated by the ORF2 protein

G. Joshi, E. Decembre, J. Brocard, C. Montpellier, M. Ferrie, O. Allatif, A.-K. Mehnert, J. Pons, D. Galiana, V. L. Dao Thi, N. Jouvenet, L. Cocquerel, M. Dreux

This study shows that Hepatitis E Virus (HEV) ORF2 protein modulates plasmacytoid dendritic cell (pDC)-mediated antiviral responses by affecting pDC recognition of infected cells.

bioRxiv · Apr 12, 2024Immunology

Targeting cellular cathepsins inhibits hepatitis E virus infection

M. Kloehn, T. Burkard, J. Janzen, J. A. Schrader, A. Goemer, R. J. P. Brown, V. L. Dao Thi, V. Kinast, Y. Brueggemann, D. Todt, E. Steinmann

This study identifies lysosomal cathepsins, particularly CTSL, as critical for HEV entry and demonstrates the antiviral efficacy of the pan-cathepsin inhibitor K11777.

bioRxiv · Nov 3, 2023 · PreprintCell Biology

A high-content RNA-based imaging assay reveals integrin beta 1 as a cofactor for cell entry of non-enveloped hepatitis E virus

R. M. Fu, Z. Engels, J. A. Wheis, J. Muerle, M. Kloehn, D. Todt, J. Hu, E. Steinmann, T. Boettler, P.-Y. Lozach, S. M. Lemon, V. L. Dao Thi

This study identifies integrin beta 1 as a cofactor for naked hepatitis E virus entry, revealing distinct endocytic pathways for naked and enveloped HEV particles.

bioRxiv · Oct 27, 2023 · PreprintMicrobiology

Efficient formation and maintenance of humoral and CD4 T cell immunity targeting the viral capsid in acute-resolving hepatitis E infection

B. Csernalabics, M. S. Marinescu, L. Maurer, L. Kelsch, J. Werner, K. Baumann, K. Zoldan, M. Panning, P. Reuken, T. Bruns, B. Bengsch, C. Neumann-Haefelin, M. Hofmann, R. Thimme, V. L. Dao Thi, T. Boettler

The paper longitudinally characterizes HEV-specific CD4 T cells and neutralizing antibodies targeting nHEV and eHEV in acute and resolved HEV infection, finding capsid-specific immunity dominates and correlates with nAb responses.

bioRxiv · Oct 19, 2023Immunology

Human pluripotent stem cell-derived hepatocyte-like cells for hepatitis D virus studies

H. Chi, B. Qu, A. Prawira, L. Maurer, J. Hu, R. M. Fu, F. A. Lempp, Z. Zhang, D. Grimm, X. Wu, S. Urban, V. L. Dao Thi

This study shows that hepatocyte-like cells derived from human pluripotent stem cells are permissive to hepatitis D virus infection and can be used to study HDV biology and test therapies.

bioRxiv · Oct 13, 2023 · PreprintMicrobiology

RBM39 shapes innate immunity through transcriptional and splicing control of key factors of the interferon response

T.-F. Li, P. Rothhaar, A. Lang, O. Gruenvogel, O. Colasanti, S. M. Olivera Ugarte, J. Traut, A. Piras, N. Acosta-Rivero, V. Goncalves Magalhaes, E. Springer, A. Betz, H.-E. Huang, J. Park, R. Qiu, , V. Lohmann

This study identifies RBM39 as a regulator of innate immunity by controlling transcription and splicing of key interferon response factors, revealing its potential as a therapeutic target.

bioRxiv · Oct 13, 2023 · PreprintImmunology